Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vanguard Funds PLC - Vanguard ESG Global Corporate Bond UCITS ETF (V3GE.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
4.2131-0.0336 (-0.79%)
At close: 08:09AM CET
Advertisement
Full screen
Previous Close4.2467
Open4.2131
Bid4.2105 x N/A
Ask4.2652 x N/A
Day's Range4.2131 - 4.2131
52 Week Range3.9363 - 4.8874
VolumeN/A
Avg. Volume0
Net AssetsN/A
NAV4.23
PE Ratio (TTM)N/A
Yield2.51%
YTD Daily Total Return3.34%
Beta (5Y Monthly)0.00
Expense Ratio (net)0.15%
Inception Date2021-05-20
  • GlobeNewswire

    Basilea announces approval for additional formulation of antifungal Cresemba® (isavuconazole) in China

    Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s license partner, Pfizer Inc.Intravenous use of Cresemba approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis following previous approval of oral dosage form Basel/Allschwil, Switzerland, June 24, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its license partner, Pfizer Inc. (NYSE: PFE, “P

  • GlobeNewswire

    Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer

    Basel/Allschwil, Switzerland, June 17, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that the sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region, exceeded the threshold triggering the first sales milestone payment for this region of USD 1.25 million. David Veitch, Basilea’s Chief Executive Officer, stated: “We are very pleased with the commercial progress

Advertisement
Advertisement